Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 5

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 31Hodgkin Disease 19Lymphoma 9Uveal Melanoma 5Neoplasms 4Sarcoma 3Neoplasm Metastasis 3Leiomyosarcoma 3Skin Neoplasms 2Skin Diseases 1Sarcoma, Synovial 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurofibrosarcoma 1Lymphoma, T-Cell, Peripheral 1Hematologic Diseases 1HIV Infections 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Dacarbazine × Clear all
NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01100528 2019-02-26

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Case Comprehensive Cancer Center

Phase 2 Completed
38 enrolled 10 charts
Dermatologic

Uveal Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT01974752 2017-01-05

SUMIT

AstraZeneca

Phase 3 Completed
152 enrolled 14 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡